坦度螺酮治疗青少年焦虑障碍的开放性研究
Efficacy and safety of tandospiron in the treatment of patients with anxiety disorder
摘要
目的 观察坦度螺酮治疗青少年焦虑障碍12周的疗效和不良反应.方法 采用开放性多中心研究方法,收集浙江中医药大学附属第二医院、浙江省中医院、杭州市第七医院等三所医院在2008年3月至2010年2月期间符合美国疾病诊断统计手册第四版(DSM-Ⅳ)中焦虑性障碍诊断的门诊患者169例,对其进行可变剂量坦度螺酮治疗,共12周.分别于治疗前和治疗后第2、4、8和12周末评定汉密尔顿焦虑量表(HAMA)、状态-特质焦虑问卷(STAI)和临床疗效总评量表(CCI)及药物疗效,记录治疗中出现的不良反应.结果 151例完成12周治疗,从治疗第2周末至第12周末,HAMA评分的减分率分别为18% ±12%、38%±16%、54%±20%、63% ±17%(均P<0.01),治疗12周末81.5%的患者能够获得显效或临床痊愈(HAMA减分率≥50%);患者12周末HAMD17评分(7±2)分明显低于人组时的(13±3)分(P<0.01),治疗期间患者出现的不良反应少(9.9%),轻微且短暂.结论 坦度螺酮是一种治疗焦虑障碍有效且安全性高的药物,可能适用于治疗青少年各种类型的焦虑障碍.
[Abstract] Objective To explore the efficacy and safety of tandospirone for adolescents with anxiety disorder.Methods In this multicenter open-label 12-week study,a total of 169 adolescents met the criteria of DSM-Ⅳ for anxiety disorder were treated with flexible dose of tandospirone.The effects and safety of treatment were assessed by the Hamilton anxiety scale (HAMA),state-trait anxiety inventor (STAI),clinical global impression (CGI) and side effects at baseline and Weeks 2,4,8 and 12.Results In 151cases completing the 12-week treatment,the scores of HAMA decreased by 18% ± 12%,38% ± 16%,54% ±20% and 63% ± 17% at Weeks 2,4,8 and 12.Significant reductions in HAMA scores were seen at Weeks 2 12 (P < 0.01 ) and marked improvement appeared in 8 1.5% cases at Week 12 (reduction rate of HAMA:50% ).At Week 12,the HAMD17 scores were markedly lower versus baseline (7 ±2 vs 13 ±3,P < 0.01 ).Adverse effect of tandospirone was scarcely found ( 9.9% ). Conclusion Tandospirone is an effective and safe anti-anxiety drug for adolescents.
年,卷(期):
2012, 92(13)
分类号:
R4
机标分类号:
R749.4
R255.2
G420
在线出版日期:
2012年7月17日